Free Trial
NASDAQ:EPRX

Eupraxia Pharmaceuticals 8/7/2024 Earnings Report

Eupraxia Pharmaceuticals logo
$5.29 -0.12 (-2.22%)
Closing price 03:50 PM Eastern
Extended Trading
$5.34 +0.05 (+0.95%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eupraxia Pharmaceuticals EPS Results

Actual EPS
-$0.17
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Eupraxia Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eupraxia Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Eupraxia Pharmaceuticals' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules.

Conference Call Resources

Eupraxia Pharmaceuticals Earnings Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Eupraxia Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eupraxia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your email.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (NASDAQ:EPRX), Inc. is a clinical-stage biotechnology company focused on developing engineered bacterial therapies for gastrointestinal and liver diseases. The company’s proprietary platform leverages synthetic biology to engineer nonpathogenic microbial strains capable of producing therapeutic molecules directly at sites of disease within the gut. By combining microbiome science with precision genetic engineering, Eupraxia aims to address conditions that have proven difficult to treat with conventional small molecules or biologics.

The company’s pipeline comprises multiple lead programs in early clinical and preclinical development. These candidates are designed to modulate immune and metabolic pathways through localized delivery of bioactive proteins and peptides. Eupraxia’s approach seeks to reduce systemic exposure and off-target effects by confining therapeutic activity to the gastrointestinal tract. Key areas of investigation include inflammatory bowel diseases, cholestatic liver disorders and other chronic GI conditions with high unmet medical need.

Headquartered in Dallas, Texas, Eupraxia Pharmaceuticals went public on the Nasdaq Global Market under the ticker symbol EPRX. The company is led by a team of experienced biopharmaceutical executives and scientists with expertise in synthetic biology, microbiome research and clinical development. Through strategic partnerships and a growing pipeline, Eupraxia aims to advance novel microbial therapies that could transform the treatment landscape for digestive and liver diseases.

View Eupraxia Pharmaceuticals Profile

More Earnings Resources from MarketBeat